Greenberg Traurig has advised UBS and Ipopema Securities on Ryvu Therapeutics' PLN 140 million new share offering. CK Legal advised Ryvu Therapeutics.
Ryvu Therapeutics is a Polish clinical-stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology. The company is listed on the Warsaw Stock Exchange. The company offered 2.38 million new shares to its shareholders, and according to Greenberg Traurig, "the offering took the form of a public offering exempted from the obligation to publish an issue prospectus." According to the firm, "investors declared subscription for all newly issued shares, with the value exceeding PLN 140 million."
According to Greenberg Traurig, "Ryvu Therapeutics intends to use the proceeds of the issue to fund its ongoing projects, in particular the development of a compound in new therapeutic indications in the area of solid tumors and AML/MDS as well as the development of its preclinical projects, discovery phase programs in the area of synthetic lethality and immune-oncology and financing its ongoing operations."
The Greenberg Traurig team included Partners Pawel Piotrowski and Rafal Sienski and Senior Associate Agata Wisniewska. Legal advice on U.S. and English law was provided by Greenberg Traurig's London-based Partners Dorothee Fischer-Appelt and James Mountain.
CK Legal's team included Managing Partner Wojciech Chabasiewicz and Counsel Anita Gwozdz.
